Motley Fool6d agobullish
AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?AbbVie still looks like a compelling buy at its all-time high.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
543last 24h
2521last 7d
483● bullish (7d)
259● bearish (7d)
197publishers
Insider Monkey38d agoneutral
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s WhyRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
Simply Wall St.42d agoneutral
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee DealAbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what...
Insider Monkey70d agoneutral
Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline ProgressAbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares. The firm mentioned AbbVie’s extensive inflammatory bowel disease pipeline as a major source of investor interest. AbbVie Inc. […]
Insider Monkey78d agoneutral
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISIAbbVie Inc. (NYSE:ABBV) is included among the Top 12 Undervalued Dividend Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. On May 15, Evercore ISI slightly trimmed its price target on AbbVie Inc. (NYSE:ABBV) from $236 […]
24/7 Wall St.82d agoneutral
Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right NowRealty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly dividend increase as proof you can collect a check and tune out the rest of the market. The underlying numbers tell a different story. The Math On O Has Quietly Broken O trades at ... Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now